RNAi Therapeutics

Arrowhead’s REDEMPLO Launch: A New Commercial Era Unfolds

Arrowhead Pharmaceuticals (ARWR) achieved $264 million in FQ1 2026 revenue, coinciding with the pivotal REDEMPLO approval, signaling a…